Format

Send to

Choose Destination
J Vis Exp. 2019 Jul 5;(149). doi: 10.3791/59696.

Physiologic Patient Derived 3D Spheroids for Anti-neoplastic Drug Screening to Target Cancer Stem Cells.

Author information

1
Department of Biomedical Engineering, University of Michigan.
2
Department of Materials Science and Engineering, University of Michigan.
3
Department of Biomedical Engineering, University of Michigan; Department of Materials Science and Engineering, University of Michigan; Rogel Cancer Center, School of Medicine, University of Michigan; Macromolecular Science and Engineering, University of Michigan; mehtagee@umich.edu.
#
Contributed equally

Abstract

In this protocol, we outline the procedure for generation of tumor spheroids within 384-well hanging droplets to allow for high-throughput screening of anti-cancer therapeutics in a physiologically representative microenvironment. We outline the formation of patient derived cancer stem cell spheroids, as well as, the manipulation of these spheroids for thorough analysis following drug treatment. Specifically, we describe collection of spheroid morphology, proliferation, viability, drug toxicity, cell phenotype and cell localization data. This protocol focuses heavily on analysis techniques that are easily implemented using the 384-well hanging drop platform, making it ideal for high throughput drug screening. While we emphasize the importance of this model in ovarian cancer studies and cancer stem cell research, the 384-well platform is amenable to research of other cancer types and disease models, extending the utility of the platform to many fields. By improving the speed of personalized drug screening and the quality of screening results through easily implemented physiologically representative 3D cultures, this platform is predicted to aid in the development of new therapeutics and patient-specific treatment strategies, and thus have wide-reaching clinical impact.

PMID:
31329171
DOI:
10.3791/59696

Supplemental Content

Full text links

Icon for MyJove Corporation
Loading ...
Support Center